UNLOAD-AMI: Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP

Sponsor
Institute for Clinical and Experimental Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT04562272
Collaborator
(none)
80
1
2
39.3
2

Study Details

Study Description

Brief Summary

Patients with anterior wall AMI treated by PCI will undergo, after successful revascularization of the infarct artery, measurement of the left ventricular pressure, and femoral angiogram. Patients with elevated LV pressure and adequate femoral access will be randomized to standard pharmacological treatment of AMI vs. mechanical unloading by Impella-CP (on top of the standard treatment) for 36-48 hours. LV unloading will be guided by measurement of PCWP by Swan-Ganz catheter. On the day 4-7, and at 3 months after the AMI, the patients will undergo SPECT and 3D-echocardiography to assess ventricular remodeling and extent of the post-infarct scar. The patients will be followed for at least 12 months for the occurrence of heart failure and adverse cardiovascular events. The study will test the hypothesis, whether the LV mechanical unloading after PCI will attenuate post-infarct scar and cardiac remodeling.

Condition or Disease Intervention/Treatment Phase
  • Procedure: LV mechanical unloading by Impella-CP
N/A

Detailed Description

  1. Eligible patients with be screened before PCI

  2. The patients with undergo coronary angiography and PCI according to common medical practice

  3. At the end of the PCI procedure, after a successful revascularization, a pigtail catheter will be used to measure LV filling pressure and to perform femoral angiography (to evaluate femoral access).

  4. Patients fulfilling angiographic and hemodynamic criteria will be randomized 1:1 to standard care vs. mechanical unloading by Impella-CP.

  5. The patients will be treated on a CCU with experience with use of Impella-CP.

  6. On the CCU, all patients will be monitored by a Swan-Ganz catheter for 48 hours.

  7. The pump speed will be adjusted to maintain the lowest tolerated PCWP while avoiding suction events.

  8. Mechanical unloading will last 36-48h. Afterwards, the Impella-CP will be explanted.

  9. All patients will receive standard pharmacotherapy of AMI, according to the guidelines.

  10. Revascularization of significant non-infarct lesions will be performed during the index hospitalization.

  11. 3D-echocardiography and Tc-SPECT (D-SPECT) will be performed on the day 5-7 of the index hospitalization. LV phasic volumes and extent of nonperfused myocardium (scar) will be evaluated automatically, using software provided by the vendor.

  12. 3D-echocardiography and Tc-SPECT will be repeated at 3 months after the AMI.

  13. The patients will be followed by out-patient check-ups every 12 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Attenuation of Post-infarct Remodeling in Patients With Acute Myocardial Infarction by Left Ventricular Mechanical Unloading Using Impella-CP
Actual Study Start Date :
Sep 21, 2020
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Mechanical unloading

Mechanical unloading by Impella-CP for 36-48 hours, on top of the standard treatment

Procedure: LV mechanical unloading by Impella-CP
The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)
Other Names:
  • Abiomed Impella-CP
  • No Intervention: Standard care

    Standard treatment of AMI after PCI according to guidelines.

    Outcome Measures

    Primary Outcome Measures

    1. Difference in the left ventricular end-systolic volume [LV end-systolic volume measured during the index hospitalization (day 5-7) and at 3 months]

      Absolute change in the LVESV measured by SPECT and compared between the groups

    2. Occurrence of LV remodeling [LV end-systolic volume measured during the index hospitalization (day 5-7) and at 3 months]

      Occurrence of LV remodeling defined by the increase of LV end-systolic volume >20%

    3. Extent of post-infarct scar [LV scar extent measured during the index hospitalization (day 5-7) and at 3 months]

      Extent of post-infarct scar measured by Tc-SPECT and compared between the groups

    Secondary Outcome Measures

    1. CV complications [during the first 5 day after AMI]

      occurence of TIMI bleeding, hemolysis, thromboembolic events

    2. heart failure [during the first 5 day after AMI]

      acute heart failure requiring inotropes or progression of cardiogenic shock

    Other Outcome Measures

    1. self-assessed dyspnea [day 1, 2 and 5]

      dyspnea reported by the patient on a Likert scale

    2. lung water [day 1, 2 and 5]

      assessment of lung water score by ultrasound

    3. maximum hs-TnT, BNP, serum lactate [during the first 5 day after AMI]

      diference in hs-TnT, BNP and lactate between the groups

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • large anterior wall AMI with estimated ischemia of <24h

    • at risk of the beginning of cardiogenic shock (SCAI A/B)

    • blood pressure <160/100 mmHg

    • no previous IM based on the patient's history

    • no previously known LV systolic dysfunction

    • assumed new LV dysfunction documented by ECHO or LVG (LVEF < 45%)

    • infarct culprit lesion at the proximal LAD, LMCA or equivalent, with TIMI <= 2 flow

    • LV end-diastolic pressure of >= 18 mmHg measured invasively

    Exclusion Criteria:
    • history of chronic LV dysfunction

    • chronic anticoagulation therapy

    • the need of IIb/IIIa blockers at the PCI

    • inadequate femoral vein access (peripheral artery disease)

    • significant valve disease or valve prosthesis

    • CPR >5 min before PCI

    • LV thrombus

    • periprocedural AMI (obliteration of large non-culprit artery during PCI)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Institute for Clinical and Experimental Medicine (IKEM) Prague Czechia 14059

    Sponsors and Collaborators

    • Institute for Clinical and Experimental Medicine

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Marek Sramko, Head of the Department of Acute Cardiology, Institute for Clinical and Experimental Medicine
    ClinicalTrials.gov Identifier:
    NCT04562272
    Other Study ID Numbers:
    • 15849/20
    First Posted:
    Sep 24, 2020
    Last Update Posted:
    Sep 24, 2020
    Last Verified:
    Sep 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Marek Sramko, Head of the Department of Acute Cardiology, Institute for Clinical and Experimental Medicine
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 24, 2020